Peptide Library

FDA-approved

Hormones & metabolism

Pegvisomant

Evidence

FDA approved

Class

Growth hormone receptor antagonist

/

Pegvisomant

KEY TAKEAWAY

Pegvisomant is a modified growth hormone analog attached to polyethylene glycol. It is sold as Somavert. The FDA approved pegvisomant (Somavert) in 2003 for acromegaly.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Growth hormone receptor antagonist

Approved for

Acromegaly

Key fact

The FDA approved pegvisomant (Somavert) in 2003 for acromegaly.

Route

Daily subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Pegvisomant is a modified growth hormone analog attached to polyethylene glycol. It is sold as Somavert.

How it works

How it works

It binds the growth hormone receptor and blocks it, which lowers IGF-1 levels.

Regulatory status

Regulatory status

The FDA approved pegvisomant (Somavert) in 2003 for acromegaly.

What it is used for

What it is used for

Acromegaly.

Side effects and risks

Side effects and risks

Liver enzyme elevations can occur and are monitored. Injection-site reactions and flu-like symptoms are reported.

Citations

Citations

U.S. FDA prescribing information for Pegvisomant. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo